

(51) International Patent Classification:

C07K 7/02 (2006.01)

C07K 5/027 (2006.01)

A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IL S2020/040711

(22) International Filing Date:

02 July 2020 (02.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/870,644

03 July 2019 (03.07.2019)

US

(71) Applicants: ICONIC THERAPEUTICS, INC. [US/US];

701 Gateway Blvd, Ste 100, South San Francisco, CA 94080 (US); ZYMEWORKS INC. [CA/CA]; 540-1385 West 8th Ave, Vancouver, British Columbia V6L 3V9 (CA).

(72) Inventors: THEUNISSEN, Jan-Willem; c/o Iconic Therapeutics, Inc., 701 Gateway Blvd, Ste 100, South San Francisco, CA 94080 (US);

CAI, Allen G.; c/o Iconic Therapeutics, Inc., 701 Gateway Blvd, Ste 100, South San Francisco, CA 94080 (US); MIGONE, Thi-Sau; c/o Iconic Therapeutics, Inc., 701 Gateway Blvd, Ste 100, South San Francisco, CA 94080 (US).

(74) Agent: MUBYANA, Kuwaho et al.; c/o Patent Administrator, Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AQ, AT, AU, AZ, BA, BB, BG, BI, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GI, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SJ, SZ, TZ, UG, ZM, ZW); Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM); European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR); OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(a))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(b))

(54) Title: ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS




FIG. 5A

(57) Abstract: Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.